Stay updated on Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial

Sign up to get notified when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0; no substantive study information changes are evident.
    Difference
    0.1%
    Check dated 2026-03-18T22:28:15.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-11T19:01:47.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    Added Primary peritoneal carcinoma as a study condition and added the Genetic and Rare Diseases Information Center as a resource. Removed the government funding lapse notice and updated the page revision to v3.4.2.
    Difference
    0.6%
    Check dated 2026-02-11T04:14:02.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    A site-wide notice regarding government funding and NIH Clinical Center operations was added. The page revision tag was updated to v3.4.1, replacing v3.4.0.
    Difference
    0.4%
    Check dated 2026-02-04T05:15:49.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The page adds a glossary display option and updates metadata labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0), replacing the previous wording (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).
    Difference
    0.2%
    Check dated 2026-01-28T03:49:55.000Z thumbnail image
  8. Check
    79 days ago
    Change Detected
    Summary
    Revision: v3.3.4 is now displayed, replacing Revision: v3.3.3. This appears to be a backend version update with no changes to the study details or user interactions on the page.
    Difference
    0.1%
    Check dated 2026-01-14T02:28:39.000Z thumbnail image

Stay in the know with updates to Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.